<DOC>
	<DOC>NCT02515630</DOC>
	<brief_summary>This study will evaluate the transfusion independence response rate in transfusion-dependent adults with myelofibrosis after treatment with momelotinib (MMB).</brief_summary>
	<brief_title>Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia, Essential</mesh_term>
	<criteria>Key Diagnosis of PMF or Post PV/ETMF Requires myelofibrosis therapy, in the opinion of the investigator High risk OR intermediate2 risk defined by dynamic international prognostic scoring system (DIPSS) OR intermediate1 risk defined by DIPSS and associated with symptomatic splenomegaly and/or hepatomegaly Transfusion dependent at baseline, defined as ≥ 4 U red blood cell (RBC) transfusion in the 8 weeks prior to first dose of MMB Acceptable organ function as evidenced by the following: Platelet Count ≥ 50 x 10^9/L Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3 x upper limit of normal (ULN) or AST or ALT ≤ 5 x ULN if liver is involved by disease process as judged by the investigator Serum creatinine ≤ 2.0 mg/dL or calculated creatinine clearance of ≥ 60 mL/min Direct bilirubin ≤ 2.0 x ULN Life expectancy of &gt; 24 weeks Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception Lactating females must agree to discontinue nursing before MMB administration Able to understand and willing to sign the informed consent form Key Prior splenectomy Splenic irradiation within 3 months prior to the first dose of MMB Prior treatment with MMB Known positive status of human immunodeficiency virus (HIV) Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrier Use of strong cytochrome P450 3A4 (CYP3A4) inducer within 2 weeks prior to the first dose of MMB Uncontrolled intercurrent illness per protocol Treatment with a Janus kinase (JAK) inhibitor within 21 days of the planned first dose of MMB Presence of peripheral neuropathy ≥ Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 Unwilling or unable to undergo a MRI per requirements in the study protocol Unwilling to consent to genomics sampling Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>